CAR T therapy extends its reach to autoimmune diseases
- PMID: 36423579
- DOI: 10.1016/j.cell.2022.10.026
CAR T therapy extends its reach to autoimmune diseases
Abstract
CAR T therapy has revolutionized the treatment of hematologic cancers. In their recent Nature Medicine paper, Mackensen et al. report the use of CAR T cells to treat systemic lupus erythematosus in five patients. This provides enthusiasm to further explore CAR T therapy beyond oncology.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests C.H.J. is an inventor on patents and/or patent applications licensed to Novartis Institutes of Biomedical Research and receives license revenue from such licenses. C.H.J is a scientific founder of Tmunity Therapeutics and Capstan Therapeutics. C.H.J is a member of the scientific advisory boards of AC Immune, Alaunos, BluesphereBio, Cabaletta, Carisma, Cartography, Cellares, Celldex, Decheng, Poseida, Verismo, and WIRB-Copernicus.
Comment on
-
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.Nat Med. 2022 Oct;28(10):2124-2132. doi: 10.1038/s41591-022-02017-5. Epub 2022 Sep 15. Nat Med. 2022. PMID: 36109639
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
